Toll Free: 1-888-928-9744
Published: Jan, 2018 | Pages:
98 | Publisher: QYResearch
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
In this report, the United States Pulmonary Hypertension Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share and growth rate of Pulmonary Hypertension Drug in these regions, from 2013 to 2025 (forecast). United States Pulmonary Hypertension Drug market competition by top manufacturers/players, with Pulmonary Hypertension Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including Sanofi Vectura Group plc Bayer AG Ikaria Inc. Proreo Pharma AG Vicore Pharma AB Biolab Sanus Farmaceutica Ltda. Hanmi Pharmaceuticals, Co. Ltd. On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into IK-3001 Sildenafil Citrate IMD IK-7002 Riociguat SAR-407899 Others On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including Clinic Hospital Others If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents United States Pulmonary Hypertension Drug Market Report 2018 1 Pulmonary Hypertension Drug Overview 1.1 Product Overview and Scope of Pulmonary Hypertension Drug 1.2 Classification of Pulmonary Hypertension Drug by Product Category 1.2.1 United States Pulmonary Hypertension Drug Market Size (Sales Volume) Comparison by Type (2013-2025) 1.2.2 United States Pulmonary Hypertension Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2017 1.2.3 IK-3001 1.2.4 Sildenafil Citrate IMD 1.2.5 IK-7002 1.2.6 Riociguat 1.2.7 SAR-407899 1.2.8 Others 1.3 United States Pulmonary Hypertension Drug Market by Application/End Users 1.3.1 United States Pulmonary Hypertension Drug Market Size (Consumption) and Market Share Comparison by Application (2013-2025) 1.3.2 Clinic 1.3.3 Hospital 1.3.4 Others 1.4 United States Pulmonary Hypertension Drug Market by Region 1.4.1 United States Pulmonary Hypertension Drug Market Size (Value) Comparison by Region (2013-2025) 1.4.2 The West Pulmonary Hypertension Drug Status and Prospect (2013-2025) 1.4.3 Southwest Pulmonary Hypertension Drug Status and Prospect (2013-2025) 1.4.4 The Middle Atlantic Pulmonary Hypertension Drug Status and Prospect (2013-2025) 1.4.5 New England Pulmonary Hypertension Drug Status and Prospect (2013-2025) 1.4.6 The South Pulmonary Hypertension Drug Status and Prospect (2013-2025) 1.4.7 The Midwest Pulmonary Hypertension Drug Status and Prospect (2013-2025) 1.5 United States Market Size (Value and Volume) of Pulmonary Hypertension Drug (2013-2025) 1.5.1 United States Pulmonary Hypertension Drug Sales and Growth Rate (2013-2025) 1.5.2 United States Pulmonary Hypertension Drug Revenue and Growth Rate (2013-2025) 2 United States Pulmonary Hypertension Drug Market Competition by Players/Suppliers 2.1 United States Pulmonary Hypertension Drug Sales and Market Share of Key Players/Suppliers (2013-2018) 2.2 United States Pulmonary Hypertension Drug Revenue and Share by Players/Suppliers (2013-2018) 2.3 United States Pulmonary Hypertension Drug Average Price by Players/Suppliers (2013-2018) 2.4 United States Pulmonary Hypertension Drug Market Competitive Situation and Trends 2.4.1 United States Pulmonary Hypertension Drug Market Concentration Rate 2.4.2 United States Pulmonary Hypertension Drug Market Share of Top 3 and Top 5 Players/Suppliers 2.4.3 Mergers & Acquisitions, Expansion in United States Market 2.5 United States Players/Suppliers Pulmonary Hypertension Drug Manufacturing Base Distribution, Sales Area, Product Type 3 United States Pulmonary Hypertension Drug Sales (Volume) and Revenue (Value) by Region (2013-2018) 3.1 United States Pulmonary Hypertension Drug Sales and Market Share by Region (2013-2018) 3.2 United States Pulmonary Hypertension Drug Revenue and Market Share by Region (2013-2018) 3.3 United States Pulmonary Hypertension Drug Price by Region (2013-2018) 4 United States Pulmonary Hypertension Drug Sales (Volume) and Revenue (Value) by Type (Product Category) (2013-2018) 4.1 United States Pulmonary Hypertension Drug Sales and Market Share by Type (Product Category) (2013-2018) 4.2 United States Pulmonary Hypertension Drug Revenue and Market Share by Type (2013-2018) 4.3 United States Pulmonary Hypertension Drug Price by Type (2013-2018) 4.4 United States Pulmonary Hypertension Drug Sales Growth Rate by Type (2013-2018) 5 United States Pulmonary Hypertension Drug Sales (Volume) by Application (2013-2018) 5.1 United States Pulmonary Hypertension Drug Sales and Market Share by Application (2013-2018) 5.2 United States Pulmonary Hypertension Drug Sales Growth Rate by Application (2013-2018) 5.3 Market Drivers and Opportunities 6 United States Pulmonary Hypertension Drug Players/Suppliers Profiles and Sales Data 6.1 Sanofi 6.1.1 Company Basic Information, Manufacturing Base and Competitors 6.1.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.1.2.1 Product A 6.1.2.2 Product B 6.1.3 Sanofi Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.1.4 Main Business/Business Overview 6.2 Vectura Group plc 6.2.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.2.2.1 Product A 6.2.2.2 Product B 6.2.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.2.4 Main Business/Business Overview 6.3 Bayer AG 6.3.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.3.2.1 Product A 6.3.2.2 Product B 6.3.3 Bayer AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.3.4 Main Business/Business Overview 6.4 Ikaria Inc. 6.4.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.4.2.1 Product A 6.4.2.2 Product B 6.4.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.4.4 Main Business/Business Overview 6.5 Proreo Pharma AG 6.5.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.5.2.1 Product A 6.5.2.2 Product B 6.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.5.4 Main Business/Business Overview 6.6 Vicore Pharma AB 6.6.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.6.2.1 Product A 6.6.2.2 Product B 6.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.6.4 Main Business/Business Overview 6.7 Biolab Sanus Farmaceutica Ltda. 6.7.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.7.2.1 Product A 6.7.2.2 Product B 6.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.7.4 Main Business/Business Overview 6.8 Hanmi Pharmaceuticals, Co. Ltd. 6.8.2 Pulmonary Hypertension Drug Product Category, Application and Specification 6.8.2.1 Product A 6.8.2.2 Product B 6.8.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Revenue, Price and Gross Margin (2013-2018) 6.8.4 Main Business/Business Overview 7 Pulmonary Hypertension Drug Manufacturing Cost Analysis 7.1 Pulmonary Hypertension Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Price Trend of Key Raw Materials 7.1.3 Key Suppliers of Raw Materials 7.1.4 Market Concentration Rate of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.2.1 Raw Materials 7.2.2 Labor Cost 7.2.3 Manufacturing Expenses 7.3 Manufacturing Process Analysis of Pulmonary Hypertension Drug 8 Industrial Chain, Sourcing Strategy and Downstream Buyers 8.1 Pulmonary Hypertension Drug Industrial Chain Analysis 8.2 Upstream Raw Materials Sourcing 8.3 Raw Materials Sources of Pulmonary Hypertension Drug Major Manufacturers in 2017 8.4 Downstream Buyers 9 Marketing Strategy Analysis, Distributors/Traders 9.1 Marketing Channel 9.1.1 Direct Marketing 9.1.2 Indirect Marketing 9.1.3 Marketing Channel Development Trend 9.2 Market Positioning 9.2.1 Pricing Strategy 9.2.2 Brand Strategy 9.2.3 Target Client 9.3 Distributors/Traders List 10 Market Effect Factors Analysis 10.1 Technology Progress/Risk 10.1.1 Substitutes Threat 10.1.2 Technology Progress in Related Industry 10.2 Consumer Needs/Customer Preference Change 10.3 Economic/Political Environmental Change 11 United States Pulmonary Hypertension Drug Market Size (Value and Volume) Forecast (2018-2025) 11.1 United States Pulmonary Hypertension Drug Sales Volume, Revenue Forecast (2018-2025) 11.2 United States Pulmonary Hypertension Drug Sales Volume Forecast by Type (2018-2025) 11.3 United States Pulmonary Hypertension Drug Sales Volume Forecast by Application (2018-2025) 11.4 United States Pulmonary Hypertension Drug Sales Volume Forecast by Region (2018-2025) 12 Research Findings and Conclusion 13 Appendix 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer
List of Tables and Figures Figure Product Picture of Pulmonary Hypertension Drug Figure United States Pulmonary Hypertension Drug Market Size (K Pcs) by Type (2013-2025) Figure United States Pulmonary Hypertension Drug Sales Volume Market Share by Type (Product Category) in 2017 Figure IK-3001 Product Picture Figure Sildenafil Citrate IMD Product Picture Figure IK-7002 Product Picture Figure Riociguat Product Picture Figure SAR-407899 Product Picture Figure Others Product Picture Figure United States Pulmonary Hypertension Drug Market Size (K Pcs) by Application (2013-2025) Figure United States Sales Market Share of Pulmonary Hypertension Drug by Application in 2017 Figure Clinic Examples Table Key Downstream Customer in Clinic Figure Hospital Examples Table Key Downstream Customer in Hospital Figure Others Examples Table Key Downstream Customer in Others Figure United States Pulmonary Hypertension Drug Market Size (Million USD) by Region (2013-2025) Figure The West Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate (2013-2025) Figure Southwest Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate (2013-2025) Figure The Middle Atlantic Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate (2013-2025) Figure New England Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate (2013-2025) Figure The South of US Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate (2013-2025) Figure The Midwest Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate (2013-2025) Figure United States Pulmonary Hypertension Drug Sales (K Pcs) and Growth Rate (2013-2025) Figure United States Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate (2013-2025) Figure United States Pulmonary Hypertension Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018) Table United States Pulmonary Hypertension Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018) Table United States Pulmonary Hypertension Drug Sales Share by Players/Suppliers (2013-2018) Figure 2017 United States Pulmonary Hypertension Drug Sales Share by Players/Suppliers Figure 2017 United States Pulmonary Hypertension Drug Sales Share by Players/Suppliers Figure United States Pulmonary Hypertension Drug Market Major Players Product Revenue (Million USD) (2013-2018) Table United States Pulmonary Hypertension Drug Revenue (Million USD) by Players/Suppliers (2013-2018) Table United States Pulmonary Hypertension Drug Revenue Share by Players/Suppliers (2013-2018) Figure 2017 United States Pulmonary Hypertension Drug Revenue Share by Players/Suppliers Figure 2017 United States Pulmonary Hypertension Drug Revenue Share by Players/Suppliers Table United States Market Pulmonary Hypertension Drug Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018) Figure United States Market Pulmonary Hypertension Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2017 Figure United States Pulmonary Hypertension Drug Market Share of Top 3 Players/Suppliers Figure United States Pulmonary Hypertension Drug Market Share of Top 5 Players/Suppliers Table United States Players/Suppliers Pulmonary Hypertension Drug Manufacturing Base Distribution and Sales Area Table United States Players/Suppliers Pulmonary Hypertension Drug Product Category Table United States Pulmonary Hypertension Drug Sales (K Pcs) by Region (2013-2018) Table United States Pulmonary Hypertension Drug Sales Share by Region (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Share by Region (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Market Share by Region in 2017 Table United States Pulmonary Hypertension Drug Revenue (Million USD) and Market Share by Region (2013-2018) Table United States Pulmonary Hypertension Drug Revenue Share by Region (2013-2018) Figure United States Pulmonary Hypertension Drug Revenue Market Share by Region (2013-2018) Figure United States Pulmonary Hypertension Drug Revenue Market Share by Region in 2017 Table United States Pulmonary Hypertension Drug Price (USD/Pcs) by Region (2013-2018) Table United States Pulmonary Hypertension Drug Sales (K Pcs) by Type (2013-2018) Table United States Pulmonary Hypertension Drug Sales Share by Type (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Share by Type (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Market Share by Type in 2017 Table United States Pulmonary Hypertension Drug Revenue (Million USD) and Market Share by Type (2013-2018) Table United States Pulmonary Hypertension Drug Revenue Share by Type (2013-2018) Figure Revenue Market Share of Pulmonary Hypertension Drug by Type (2013-2018) Figure Revenue Market Share of Pulmonary Hypertension Drug by Type in 2017 Table United States Pulmonary Hypertension Drug Price (USD/Pcs) by Types (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Growth Rate by Type (2013-2018) Table United States Pulmonary Hypertension Drug Sales (K Pcs) by Application (2013-2018) Table United States Pulmonary Hypertension Drug Sales Market Share by Application (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Market Share by Application (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Market Share by Application in 2017 Table United States Pulmonary Hypertension Drug Sales Growth Rate by Application (2013-2018) Figure United States Pulmonary Hypertension Drug Sales Growth Rate by Application (2013-2018) Table Sanofi Basic Information List Table Sanofi Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Sanofi Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Sanofi Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Sanofi Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Vectura Group plc Basic Information List Table Vectura Group plc Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Vectura Group plc Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Vectura Group plc Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Vectura Group plc Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Bayer AG Basic Information List Table Bayer AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Bayer AG Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Bayer AG Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Bayer AG Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Ikaria Inc. Basic Information List Table Ikaria Inc. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Ikaria Inc. Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Ikaria Inc. Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Ikaria Inc. Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Proreo Pharma AG Basic Information List Table Proreo Pharma AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Proreo Pharma AG Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Proreo Pharma AG Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Proreo Pharma AG Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Vicore Pharma AB Basic Information List Table Vicore Pharma AB Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Vicore Pharma AB Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Vicore Pharma AB Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Vicore Pharma AB Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Biolab Sanus Farmaceutica Ltda. Basic Information List Table Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Hanmi Pharmaceuticals, Co. Ltd. Basic Information List Table Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018) Figure Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales Growth Rate (2013-2018) Figure Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales Market Share in United States (2013-2018) Figure Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Revenue Market Share in United States (2013-2018) Table Production Base and Market Concentration Rate of Raw Material Figure Price Trend of Key Raw Materials Table Key Suppliers of Raw Materials Figure Manufacturing Cost Structure of Pulmonary Hypertension Drug Figure Manufacturing Process Analysis of Pulmonary Hypertension Drug Figure Pulmonary Hypertension Drug Industrial Chain Analysis Table Raw Materials Sources of Pulmonary Hypertension Drug Major Players/Suppliers in 2017 Table Major Buyers of Pulmonary Hypertension Drug Table Distributors/Traders List Figure United States Pulmonary Hypertension Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025) Figure United States Pulmonary Hypertension Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025) Figure United States Pulmonary Hypertension Drug Price (USD/Pcs) Trend Forecast (2018-2025) Table United States Pulmonary Hypertension Drug Sales Volume (K Pcs) Forecast by Type (2018-2025) Figure United States Pulmonary Hypertension Drug Sales Volume (K Pcs) Forecast by Type (2018-2025) Figure United States Pulmonary Hypertension Drug Sales Volume (K Pcs) Forecast by Type in 2025 Table United States Pulmonary Hypertension Drug Sales Volume (K Pcs) Forecast by Application (2018-2025) Figure United States Pulmonary Hypertension Drug Sales Volume (K Pcs) Forecast by Application (2018-2025) Figure United States Pulmonary Hypertension Drug Sales Volume (K Pcs) Forecast by Application in 2025 Table United States Pulmonary Hypertension Drug Sales Volume (K Pcs) Forecast by Region (2018-2025) Table United States Pulmonary Hypertension Drug Sales Volume Share Forecast by Region (2018-2025) Figure United States Pulmonary Hypertension Drug Sales Volume Share Forecast by Region (2018-2025) Figure United States Pulmonary Hypertension Drug Sales Volume Share Forecast by Region in 2025 Table Research Programs/Design for This Report Figure Bottom-up and Top-down Approaches for This Report Figure Data Triangulation Table Key Data Information from Secondary Sources Table Key Data Information from Primary Sources
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.